ArticleMolecular biology reports2026
SMAD4 mRNA expression as a diagnostic biomarker in non-small cell lung cancer.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNon-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related mortality worldwide, largely due to late-stage diagnosis. Although histopathology is the gold standard, there is a need for reliable molecular biomarkers to improve early detection and support less invasive diagnostic strategies. SMAD4, a known tumor suppressor, has been implicated in cancer progression, but its diagnostic relevance in NSCLC requires further investigation. This study aimed to evaluate SMAD4 mRNA expression in NSCLC and assess its association with clinicopathological features and its potential as a tissue-based diagnostic biomarker. METHODS AND
resultsSMAD4 mRNA expression was quantified using qPCR in human lung cell lines and tissue samples from 49 NSCLC patients. Findings were validated using transcriptomic datasets from TCGA and GTEx. Associations with clinicopathological parameters were analyzed, and diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis. Proteomic validation was performed using CPTAC data. SMAD4 mRNA expression was significantly downregulated in NSCLC tissues compared to adjacent non-tumor tissues, consistent across clinical samples, cell lines, and public datasets. Expression levels varied significantly across histological subtypes and tumor grades. ROC analysis demonstrated good discriminatory ability in the patient cohort (AUC = 0.7995; 95% CI: 0.7056-0.8933), which was confirmed in the GSE32863 validation cohort (AUC = 0.8047; 95% CI: 0.7236-0.8858). Analysis of publicly available CPTAC proteomic data confirmed reduced SMAD4 protein levels, supporting concordant transcriptomic and proteomic downregulation.
conclusionsSMAD4 mRNA shows promise as a diagnostic biomarker for NSCLC. Further validation in larger cohorts and exploration of its application in minimally invasive diagnostics, such as liquid biopsy, are warranted.
Indexed as
Identifiers
42631856What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.